Skip to content
Screener

Intellia Therapeutics NTLA Operating Lease Liabilities

Operating Lease Liabilities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$262.48M+59.7%
ALN
Alnylam PharmaceuticalsALNY
$210.5M-6.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$183.56M-9.1%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$135.85M-6.3%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$2.2M+66.5%
Prime Medicine logo
Prime MedicinePRME
$103.51M-8.0%

Other financials

Income statement

See full
Revenue$7.7M-46.2%
Operating income-$112.8M-2.5%
Net income-$106.6M-5.3%
EPS (diluted)-$0.80+18.4%

Balance sheet

See full
Cash & equivalents$106.1M-32.0%
Total debt$73.4M-28.4%
Total equity$727.7M+202%
Total assets$857.2M-4.6%

Cash flow

See full
Operating cash flow-$83.1M+16.6%
CapEx$1.8M+657%
Free cash flow-$84.9M+15.0%

Valuation

See full
Market cap$1.57B+33.3%
Enterprise value$1.54B+36.8%
P/S26.4×+4.1×

Profitability

See full
Operating margin-711.7%-149pp
Net margin-672.2%-139pp
FCF margin-586%-123pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×—
Current ratio6.6×+1.5×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337952
Line itemJune 30,2026December 31,2025
Current portion of operating lease liability23,34426,480
Current portion of deferred revenue-7,290
Total current liabilities79,392103,884
Long-term operating lease liability50,06666,849
Total liabilities129,458170,733
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.0001 par value; 240,000,000 shares authorized at June 30, 2026 and December 31, 2025; 140,018,200 and 116,317,060 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1412

Item 1. Financial Statements

FAQ

What is Intellia Therapeutics's operating lease liabilities?
Intellia Therapeutics (NTLA) reported operating lease liabilities of $50.07M in Q2 2026.
How has Intellia Therapeutics's operating lease liabilities changed year-over-year?
Intellia Therapeutics's operating lease liabilities decreased by 33.8% year-over-year, from $75.6M to $50.07M.
What is the long-term trend for Intellia Therapeutics's operating lease liabilities?
Over 5 years (2020 to 2025), Intellia Therapeutics's operating lease liabilities has grown at a 14.7% compound annual growth rate (CAGR), from $33.61M to $66.85M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Intellia Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude